X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Indoco Remedies with Geojit BNP Paribas - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs GEOJIT BNP PARIBAS - Comparison Results

INDOCO REMEDIES    Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES GEOJIT BNP PARIBAS INDOCO REMEDIES/
GEOJIT BNP PARIBAS
 
P/E (TTM) x 31.2 35.6 87.7% View Chart
P/BV x 3.7 5.2 71.5% View Chart
Dividend Yield % 0.6 0.1 599.8%  

Financials

 INDOCO REMEDIES   GEOJIT BNP PARIBAS
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-17
GEOJIT BNP PARIBAS
Mar-14
INDOCO REMEDIES/
GEOJIT BNP PARIBAS
5-Yr Chart
Click to enlarge
High Rs36027 1,347.3%   
Low Rs24916 1,547.2%   
Sales per share (Unadj.) Rs119.09.1 1,304.8%  
Earnings per share (Unadj.) Rs8.4-3.2 -260.8%  
Cash flow per share (Unadj.) Rs15.2-2.7 -558.5%  
Dividends per share (Unadj.) Rs1.600.10 1,600.0%  
Dividend yield (eoy) %0.50.5 112.5%  
Book value per share (Unadj.) Rs70.719.0 371.8%  
Shares outstanding (eoy) m92.15228.36 40.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.62.3 109.0%   
Avg P/E ratio x36.4-6.7 -545.5%  
P/CF ratio (eoy) x20.0-7.9 -254.7%  
Price / Book Value ratio x4.31.1 382.6%  
Dividend payout %19.1-3.1 -613.6%   
Avg Mkt Cap Rs m28,0834,893 574.0%   
No. of employees `0006.02.5 241.9%   
Total wages/salary Rs m2,167715 303.2%   
Avg. sales/employee Rs Th1,817.0834.9 217.6%   
Avg. wages/employee Rs Th359.0286.4 125.3%   
Avg. net profit/employee Rs Th127.7-293.5 -43.5%   
INCOME DATA
Net Sales Rs m10,9682,083 526.5%  
Other income Rs m40242 16.4%   
Total revenues Rs m11,0072,325 473.4%   
Gross profit Rs m1,565553 282.9%  
Depreciation Rs m633110 577.4%   
Interest Rs m6225 249.4%   
Profit before tax Rs m909661 137.7%   
Minority Interest Rs m044 0.0%   
Prior Period Items Rs m0-4 0.0%   
Extraordinary Inc (Exp) Rs m0-1,213 0.0%   
Tax Rs m139220 63.1%   
Profit after tax Rs m771-732 -105.2%  
Gross profit margin %14.326.5 53.7%  
Effective tax rate %15.333.3 45.8%   
Net profit margin %7.0-35.2 -20.0%  
BALANCE SHEET DATA
Current assets Rs m5,7254,968 115.2%   
Current liabilities Rs m5,4542,486 219.4%   
Net working cap to sales %2.5119.1 2.1%  
Current ratio x1.02.0 52.5%  
Inventory Days Days620-  
Debtors Days Days72199 36.0%  
Net fixed assets Rs m5,307539 984.7%   
Share capital Rs m184228 80.8%   
"Free" reserves Rs m6,3313,896 162.5%   
Net worth Rs m6,5164,343 150.0%   
Long term debt Rs m1,3230-   
Total assets Rs m11,9707,228 165.6%  
Interest coverage x15.627.5 56.8%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.90.3 318.0%   
Return on assets %7.0-9.8 -71.1%  
Return on equity %11.8-16.9 -70.1%  
Return on capital %12.4-11.2 -110.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m4,5071 363,459.7%   
Fx outflow Rs m1,1415 22,828.0%   
Net fx Rs m3,366-4 -89,508.0%   
CASH FLOW
From Operations Rs m886378 234.7%  
From Investments Rs m-1,706-344 496.4%  
From Financial Activity Rs m1,316-713 -184.5%  
Net Cashflow Rs m497-679 -73.2%  

Share Holding

Indian Promoters % 59.2 30.6 193.5%  
Foreign collaborators % 0.0 33.5 -  
Indian inst/Mut Fund % 12.5 0.4 3,125.0%  
FIIs % 6.0 2.4 250.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 33.2 67.5%  
Shareholders   12,805 36,145 35.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   FINOLEX IND.  CCL INTERNATIONAL  IL&FS INV. MANAGERS  CHOLAMANDALAM INVEST.  EDELWEISS FINANCIAL  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Feb 23, 2018 (Close)

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES 5-YR ANALYSIS

COMPARE INDOCO REMEDIES WITH

MARKET STATS